EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access

Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized Trial

Brooke A Jarrett iD, Kate Shearer, Katlego Motlhaoleng, Sandy Chon, Gaolaolwe Gabriel Letuba, Cokiswa Qomfo, Lawrence H Moulton, Silvia Cohn, Limakatso Lebina, Richard E Chaisson, Ebrahim Variava, Neil A Martinson und 1 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae268 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Brooke A Jarrett und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: HIV Infections, Tuberculin Test, Tuberculosis. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, U.S. National Institute of Mental Health, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tuberculosis (TB) preventive therapy (TPT) reduces the risk of TB disease in people with human immunodeficiency virus (HIV), yet uptake has been suboptimal in many countries. We assessed whether QuantiFERON Gold In-Tube (QGIT) during routine HIV care increased TB infection (TBI) testing and TPT prescriptions.

Methods

This parallel-arm, 1:1 cluster-randomized controlled trial compared the standard-of-care tuberculin skin test to QGIT in South Africa. We enrolled consenting, TPT-eligible adults diagnosed with HIV ≤30 days prior and used intention-to-treat analyses for the outcomes: proportion of patients with documented TBI results, proportion with documented TPT, and time from enrollment to outcomes.

Findings

We enrolled 2232 patients across 14 clinics from November 2014 to May 2017 (58% in intervention clinics). At 24 months of follow-up, more participants in intervention clinics had TBI results (69% vs 2%, P < .001) and TPT prescriptions (45% vs 30%, P = .13) than control clinics. Controlling for baseline covariates, intervention clinics had 60% (95% confidence interval, 51–68; P < .001) more participants with TBI results and 12% (95% confidence interval, −6 to 31; P = .18) more with TPT prescriptions. Among participants with results, those in intervention clinics received results and TPT faster (intervention: median of 6 and 29 days after enrollment vs control: 21 and 54 days, respectively).

Interpretation

In this setting, QGIT in routine HIV care resulted in more patients with TBI results. Clinicians also initiated more people with HIV on TPT in QGIT intervention clinics, and did so more quickly, than the control arm. Clinical Trials Registration NCT02119130.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsTuberculin TestTuberculosisHumansMaleSouth AfricaFemaleAdultInterferon-gamma Release TestsMiddle AgedAntitubercular Agents

Stichwörter der Autor:innen

HIVinterferon-gamma release testslatent tuberculosisprevention and controltuberculin test

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore Maryland, USA.
  • Perinatal HIV Research Unit, The University of the Witwatersrand, Soweto, South Africa.
  • Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Department of Internal Medicine, Klerksdorp-Tshepong Hospital Complex, Klerksdorp, South Africa.

ORCID-Profile: Brooke A Jarrett

Förderung

  • NIMH NIH HHS
  • U.S. National Institute of Mental Health
  • NIH
  • U.S. National Institute of Allergy and Infectious Diseases
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS

Zitieren

APA

Jarrett, B. A., Shearer, K., Motlhaoleng, K., Chon, S., Letuba, G. G., Qomfo, C., Moulton, L. H., Cohn, S., Lebina, L., Chaisson, R. E., Variava, E., Martinson, N. A., & Golub, J. E. (2024). Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae268

Vancouver

Jarrett BA, Shearer K, Motlhaoleng K, Chon S, Letuba GG, Qomfo C, et al. Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae268

BibTeX
@article{Jarrett2024,
  author = {Jarrett, Brooke A and Shearer, Kate and Motlhaoleng, Katlego and Chon, Sandy and Letuba, Gaolaolwe Gabriel and Qomfo, Cokiswa and Moulton, Lawrence H and Cohn, Silvia and Lebina, Limakatso and Chaisson, Richard E and Variava, Ebrahim and Martinson, Neil A and Golub, Jonathan E},
  title = {Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized Trial},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae268}
}
Kostenlos starten →